TY - JOUR
T1 - Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab.
AU - Taverna, Josephine A.
AU - Lerner, Adam
AU - Bhawan, Jag
AU - Demierre, Marie France
PY - 2007/7
Y1 - 2007/7
N2 - Rituximab is a humanized monoclonal antibody directed against CD20-positive B cells and originally developed for the treatment of non-Hodgkins lymphoma. We report a case of severe mucous membrane pemphigoid responsive to rituximab infusions. The clinical presentation, etiology, and management options for mucous membrane pemphigoid are also discussed.
AB - Rituximab is a humanized monoclonal antibody directed against CD20-positive B cells and originally developed for the treatment of non-Hodgkins lymphoma. We report a case of severe mucous membrane pemphigoid responsive to rituximab infusions. The clinical presentation, etiology, and management options for mucous membrane pemphigoid are also discussed.
UR - http://www.scopus.com/inward/record.url?scp=34548836595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548836595&partnerID=8YFLogxK
M3 - Article
C2 - 17763598
AN - SCOPUS:34548836595
SN - 1545-9616
VL - 6
SP - 731
EP - 732
JO - Journal of drugs in dermatology : JDD
JF - Journal of drugs in dermatology : JDD
IS - 7
ER -